T2D Treatment Tied to Cardio-Renal Risk
, and the benefits of the drugs,” Vandvik said. “experts did not find drugs clinically effective [in those patients]and they will also represent a waste of precious health resources for patients and society.”
New Guidance Tailors Diabetes Treatment to Individual Risk
By Dr. Jennifer Chen, Pulitzer Prize-Winning Chief Editor
The landscape of type 2 diabetes (T2D) management is undergoing a significant shift, with new guidance emphasizing a personalized approach to prevent cardiovascular (CV) and renal complications. These recommendations, published as part of the BMJ’s “Rapid Recommendations” initiative, represent the first international living guidelines on this topic, meaning they will be dynamically updated to reflect the latest evidence.
With T2D significantly linked to multiorgan morbidity and ranking as the ninth leading cause of death, preventing CV and kidney complications is paramount.Recent years have seen transformative advancements in T2D treatment with drugs like SGLT2 inhibitors, GLP-1 receptor agonists (RAs), finerenone (a nonsteroidal selective mineralocorticoid RA), and tirzepatide (a dual glucose-dependent insulinotropic polypeptide/GLP-1 RA).
However, the rapid pace of new evidence necessitates continuously updated guidelines. This new guidance, created by an international panel of clinicians, methodologists, and patient partners, is based on a systematic review and network meta-analysis of nearly half a million adults with T2D across 869 randomized controlled trials, involving 63 medications and 26 outcomes.
Key Recommendations Based on Risk Level:
The panel’s conclusions are stratified by patient risk:
- High Risk: For patients with established cardiovascular disease (CVD) and/or chronic kidney disease (CKD), or established heart failure, the use of SGLT2 inhibitors or GLP-1 RAs is strongly recommended. Finerenone is also recommended, but with a weaker recommendation, for adults with CKD. As Dr. Vandvik noted, the cardiovascular and kidney benefits of GLP-1 RAs are comparable to those of SGLT2 inhibitors.
- Moderate Risk: For patients with multiple CV risk factors but without established CVD or CKD, a weak recommendation supports the use of SGLT2 inhibitors or GLP-1 RAs. Finerenone is not recommended in this group.
- Low Risk: For patients with three or fewer CV risk factors, the panel recommends against the use of SGLT2 inhibitors and GLP-1 ras.
The Importance of Individualized Treatment
The guidelines highlight a crucial point: the benefits of these powerful medications must be weighed against potential harms. As Dr. Vandvik emphasized, it’s essential to avoid both undertreatment in high-risk patients and overtreatment in those at low risk.The increasing popularity of newer drugs, particularly GLP-1 RAs, means clinicians must carefully consider each patient’s individual profile to ensure appropriate and effective care.
This dynamic,evidence-based approach represents a significant step forward in diabetes management,promising to improve outcomes and quality of life for millions.